Generation Bio Co. Common Stock
GBIOGeneration Bio Co. (GBIO) is a biotech company focused on developing gene therapy solutions for genetic diseases. Using their proprietary non-viral delivery platform, they aim to develop durable and safe treatments for patients with serious unmet medical needs.
Company News
Monteverde & Associates PC, a class action securities firm, has launched investigations into four merger transactions: First Foundation Inc.'s sale to FirstSun Capital Bancorp, Confluent Inc.'s acquisition by IBM, Generation Bio Co.'s sale to XOMA Royalty Corporation, and Contango Ore Inc.'s merger with Dolly Varden Silver Corporation. The firm i...
XOMA Royalty Corporation announced an agreement to acquire Generation Bio for $4.2913 per share, with additional contingent value rights for stockholders. The acquisition is expected to close in February 2026 and includes potential milestone and royalty payments.
Generation Bio, a biotechnology company, announced that its president and CEO will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on August 13th, 2024.
Generation Bio (GBIO) delivered earnings and revenue surprises of -211.11% and 34.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- Oral presentation at ASGCT described selective, high levels of therapeutic transgene delivery to T cells in vivo by cell-targeted lipid nanoparticle (ctLNP)
